INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
GP
Corporate insider

Greenleaf Peter

DirectorCIK 0001363683

EDGAR filingsOpen in network
Disclosed transactions6
Buys / sells0 / 5
Max Insider Score20
Connections with evidence2

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
GP
Greenleaf PeterDirector
ALTAltimmune, Inc.
Grant or award
A—
160.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Altimmune, Inc.Director · Nov 4, 2026
  • Insider ofevidence
    Pelthos Therapeutics Inc.Director · Apr 6, 2026
11
GP
Greenleaf PeterDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL
$17K
797 sh
Oct 2, 2026
Oct 6, 2026
traded Oct 2, 2026
+4d
SEC FORM 4

Evidence

17
GP
Greenleaf PeterDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$19K
712 sh
Jul 2, 2026Jul 7, 2026
traded Jul 2, 2026
+5dSEC FORM 4

Evidence

17
GP
Greenleaf PeterDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$2,318
85 sh
Jul 2, 2026Jul 7, 2026
traded Jul 2, 2026
+5dSEC FORM 4

Evidence

20
GP
Greenleaf PeterDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$8,616
420 sh
Apr 2, 2026Apr 6, 2026
traded Apr 2, 2026
+4dSEC FORM 4

Evidence

20
GP
Greenleaf PeterDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$8,053
377 sh
Apr 2, 2026Apr 6, 2026
traded Apr 2, 2026
+4dSEC FORM 4

Evidence